ArticleBMC infectious diseases2025
Provider cost estimation of leptospirosis at district general hospital Monaragala, Sri Lanka.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rising number of leptospirosis patients and escalating healthcare costs strain the sustainability of free healthcare systems in developing countries like Sri Lanka, posing significant challenges to resource allocation and financial stability in these regions. The objective of this study is to assess the healthcare provider's cost of managing leptospirosis at the District General Hospital, Monaragala, Sri Lanka.
methodsA hospital-based cost estimation study was conducted in DGH Monaragala using the scenario building technique, to assess the provider cost of laboratory confirmed leptospirosis patients using three standard management profiles as uncomplicated ward treated, complicated ward treated and ICU treated.
resultsThe provider cost per uncomplicated leptospirosis patient treated in the ward was Rs. 5,449.39 per day (Rs. 5,993 with 10% inflation), totaling Rs. 21,797.54 for an average 4-day stay (Rs. 23,976 with inflation). For complicated cases, the cost per day was Rs. 5,695.35 (Rs. 6,264 with 10% inflation), with a total of Rs. 39,867.43 for an average 7-day stay (Rs. 43,853 with inflation). ICU costs varied by complication: renal (Rs. 26,538.79/day), cardiac (Rs. 28,212.39/day), pulmonary (Rs. 29,657.10/day), neurological (Rs. 26,444.85/day), and multi-organ failure (Rs. 28,363.17/day). The total provider cost for laboratory-confirmed leptospirosis cases at DGH Monaragala was Rs. 7,916,564.52, with 34.7% allocated to managing 11 complicated ICU cases. CONCLUSIONS AND RECOMMENDATIONS: The provider cost of leptospirosis in DGH Monaragala was high. Given the inherent challenges in limiting exposure, it is imperative that control efforts prioritize early detection and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.